Arcutis Biotherapeutics Inc (ARQT) stock has risen 21.11% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives ARQT stock a score of 76 out of a possible 100.
That rank is mainly influenced by a long-term technical score of 86. ARQT's rank also includes a fundamental score of 86. In addition to the average rating from Wall Street analysts, ARQT stock has a mean target price of 59.333. This means analysts expect the stock to increase 78.34% over the next 12 months. The short-term technical score for ARQT is 56.
What's Happening with ARQT Stock Today
Arcutis Biotherapeutics Inc (ARQT) stock has fallen -5.05% while the S&P 500 has fallen -0.15% as of 11:50 AM on Wednesday, Mar 3. ARQT has fallen -$1.77 from the previous closing price of $35.04 on volume of 120,135 shares. Over the past year the S&P 500 is up 28.67% while ARQT has risen 21.11%. ARQT lost -$3.80 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Arcutis Biotherapeutics Inc (ARQT) Stock.
